Anixa Biosciences, Inc. (ANIX)
NASDAQ: ANIX · Real-Time Price · USD
2.480
-0.140 (-5.34%)
At close: Jun 5, 2026, 4:00 PM EDT
2.590
+0.110 (4.44%)
After-hours: Jun 5, 2026, 7:10 PM EDT
Anixa Biosciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
4
Market Cap
83.15M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Oct 31, 2025 | - | - | - |
| Oct 31, 2024 | - | - | - |
| Oct 31, 2023 | 210.00K | - | - |
| Oct 31, 2022 | - | - | - |
| Oct 31, 2021 | 512.00K | - | - |
| Oct 31, 2020 | - | - | - |
| Oct 31, 2019 | 250.00K | -862.50K | -77.53% |
| Oct 31, 2018 | 1.11M | 750.00K | 206.90% |
| Oct 31, 2017 | 362.50K | 62.50K | 20.83% |
| Oct 31, 2016 | 300.00K | -8.96M | -96.76% |
| Oct 31, 2015 | 9.26M | 5.59M | 152.36% |
| Oct 31, 2014 | 3.67M | 3.28M | 843.12% |
| Oct 31, 2013 | 388.85K | -551.16K | -58.63% |
| Oct 31, 2012 | 940.01K | -63.18K | -6.30% |
| Oct 31, 2011 | 1.00M | 272.52K | 37.30% |
| Oct 31, 2010 | 730.68K | -325.13K | -30.79% |
| Oct 31, 2009 | 1.06M | -1.01M | -48.83% |
| Oct 31, 2008 | 2.06M | 1.58M | 323.77% |
| Oct 31, 2007 | 486.85K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| ImmuCell | 29.93M |
| Pelthos Therapeutics | 27.70M |
| Atara Biotherapeutics | 23.14M |
| Rani Therapeutics Holdings | 3.17M |
| Rallybio | 858.00K |
ANIX News
- 5 days ago - Anixa Biosciences: CIPO issues Notice of Allowance for patent - TheFly
- 5 days ago - Anixa Biosciences Strengthens International Patent Protection for Ovarian Cancer Vaccine Technology with Canadian Notice of Allowance - PRNewsWire
- 26 days ago - Anixa Biosciences’ lira-cel shows positive survival data in ovarian cancer - TheFly
- 26 days ago - Anixa Biosciences Reports Updated Positive Survival Observations from Ongoing Phase 1 Trial of Lira-cel Ovarian Cancer CAR-T Therapy - PRNewsWire
- 5 weeks ago - Anixa Biosciences Interview to Air on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV - PRNewsWire
- 5 weeks ago - Anixa Biosciences awarded patent for breast cancer vaccine in Mexico - TheFly
- 5 weeks ago - Anixa Biosciences Announces Issuance of Mexican Patent Covering Breast Cancer Vaccine Technology - PRNewsWire
- 6 weeks ago - Anixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy at the International Society for Cell & Gene Therapy 2026 Annual Meeting - PRNewsWire